Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Pre-hospital loading with ticagrelor/prasugrel trumps clopidogrel in STEMI patients

28 Jun 2020

Pre-hospital loading with ticagrelor or prasugrel reduces infarct size and greater myocardial salvage index in patients with ST-elevation myocardial infarction (STEMI) relative to clopidogrel, a recent study has found.

The study included STEMI patients who were loaded with either clopidogrel (n=351; mean age, 58.8±10.6 years) or ticagrelor/prasugrel (n=342; mean age, 57.8±10.4 years) in the ambulance before receiving primary percutaneous coronary injury. Cardiac magnetic resonance (CMR) was used in the calculation of infarct size and the myocardial salvage index. Outcomes were measured at baseline and after 3 months.

At baseline, all CMR findings were comparable between the clopidogrel and ticagrelor/prasugrel groups, except for left ventricular mass index, which was significantly higher in the latter group (p=0.002).

By the 3-month follow-up, infarct size was significantly lower in the ticagrelor/prasugrel group (10.0 vs 12.9 percent of left ventricular mass; p<0.001), while the myocardial salvage index was significantly higher (71 percent vs 66 percent; p<0.001). Left ventricular mass index remained significantly elevated in the ticagrelor/prasugrel group (p=0.003).

These differences were reported despite no significant gaps in the time to CMR between the clopidogrel and ticagrelor/prasugrel groups (p=0.18). Agent choice had no significant effect on left ventricular ejection fraction, and left ventricular end-diastolic and end-systolic volume indices.

“This is a retrospective study with non-prespecified sub-analysis. Antiplatelet treatment was not randomized. No specific data were available on the timing of loading in relation to symptom onset and time of wiring/PCI,” the researchers said, referring to the study’s limitations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.